Literature DB >> 2507916

The effect of cyclosporine on the use of hospital resources for kidney transplantation.

J Showstack1, P Katz, W Amend, L Bernstein, H Lipton, M O'Leary, A Bindman, O Salvatierra.   

Abstract

Over the past decade the clinical results of kidney transplantation have improved substantially, with much of the benefit being attributed to the introduction in late 1983 of the immunosuppressive drug cyclosporine. To assess the effect of cyclosporine on the use of hospital services, we studied 702 patients who received kidney transplants at the University of California, San Francisco, between July 1982 and June 1986. All services were priced in constant 1985 dollars, and multiple regression analysis was used to adjust for changing patient and hospital characteristics. The introduction of cyclosporine for patients receiving kidneys from cadavers was associated with a significantly shorter adjusted mean postoperative stay (26.4 days as compared with 37.0 for patients not taking the drug; P less than 0.0001) and lower adjusted mean hospital charges ($28,649 as compared with $37,895; P less than 0.0001), although cyclosporine was not associated with changes in the use of services by patients who received transplants from living related donors. Cyclosporine was also associated with a reduction in the use of certain ancillary services, such as laboratory tests and radiographic procedures. In patients without diabetes who received cadaver kidneys, a sequential cyclosporine regimen (in which a combination of antilymphoblast globulin, prednisone, and azathioprine was given before cyclosporine) reduced the use of hospital services even more than did a cyclosporine regimen in which the combination was not given. The results suggest that new medications, such as cyclosporine, that reduce the frequency of complications and improve outcomes may also reduce the use of hospital resources.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507916     DOI: 10.1056/NEJM198910193211605

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  8 in total

Review 1.  Emerging indications for the use of cyclosporin in organ transplantation and autoimmunity.

Authors:  P A Keown
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

2.  Detection of noncovalent FKBP-FK506 and FKBP-Rapamycin complexes by capillary electrophoresis-mass spectrometry and capillary electrophoresis-tandem mass spectrometry.

Authors:  Y L Hsieh; J Cai; Y T Li; J D Henion; B Ganem
Journal:  J Am Soc Mass Spectrom       Date:  1995-02       Impact factor: 3.109

Review 3.  Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.

Authors:  J E Frampton; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 4.  The clinical and economic potential of cyclosporin drug interactions.

Authors:  J E Martin; A J Daoud; T J Schroeder; M R First
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

5.  Cloning, expression, and purification of human cyclophilin in Escherichia coli and assessment of the catalytic role of cysteines by site-directed mutagenesis.

Authors:  J Liu; M W Albers; C M Chen; S L Schreiber; C T Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

Review 6.  Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.

Authors:  A J Coukell; G L Plosker
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

Review 7.  Neural roles of immunophilins and their ligands.

Authors:  D M Sabatini; M M Lai; S H Snyder
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

8.  An intelligent and cost-effective computer dosing system for individualizing FK506 therapy in transplantation and autoimmune disorders.

Authors:  J McMichael; R Lieberman; H Doyle; J McCauley; J Fung; T E Starzl
Journal:  J Clin Pharmacol       Date:  1993-07       Impact factor: 3.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.